Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 3-month Blinded, Randomized, Multicenter, Placebo-controlled Study to Evaluate the Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Influenza Vaccination and Tetanus Toxoid Booster Injection in Patients With Relapsing Forms of Multiple Sclerosis (MS)

NCT01199861 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT01199861
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01199861 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 3-month Blinded, Randomized, Multicenter, Placebo-controlled Study to Evaluate the Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Influenza Vaccination and Tetanus Toxoid Booster Injection in Patients With Relapsing Forms of Multiple Sclerosis (MS)
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2010
Completion date
May 31, 2011
Enrollment
138 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing multiple sclerosis